Which peptide classes appear most in weight-loss research literature? A side-by-side reference on GLP-1, dual/triple agonists, amylin analogs and lipolytic fragments.
Weight-loss research peptides fall into four mechanistic classes. Each engages a distinct arm of the metabolic system, and each has a distinct pharmacokinetic profile that shapes study design.
| Class | Example | Primary mechanism | Half-life (research) |
|---|---|---|---|
| GLP-1 mono-agonist | Semaglutide | GLP-1R agonism | ~7 days |
| Dual incretin | Tirzepatide | GIP + GLP-1R agonism | ~5 days |
| Triple incretin | Retatrutide | GIP + GLP-1 + GCG-R | ~6 days |
| Amylin analog | Cagrilintide | Amylin/CT receptor | ~7 days |
| Lipolytic hGH fragment | AOD-9604 | hGH176-191 lipolysis | Short (minutes) |
| NNMT inhibitor | 5-Amino-1MQ | Nicotinamide N-methyltransferase inhibition | Small molecule |
What separates the classes in research
- Incretin agonists influence appetite, gastric emptying and glucose-dependent insulin release.
- Amylin analogs act on satiety and slow gastric emptying via a separate receptor.
- Lipolytic fragments target adipocyte β3-adrenergic-like pathways without engaging the full GH receptor.
- NNMT inhibitors modulate adipocyte energy metabolism through the SAM/NAD+ axis.
Documentation to expect on every batch
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
